It stems from GLP-1 receptors in the gut and brainstem that slow gastric emptying and amplify satiety signals the same mechanism responsible for reduced appetite and weight loss
In particular, two short-acting formulations of Lixisenatide and Exenatide and four long acting preparations of Exenatide, Liraglutide, Dulaglutide and the most recent and successful Semaglutide, were approved in October, 2017 for the North American markets by FDA 1 (25, 185)
Cagrilintide demonstrated significant reductions in HbA1c levels alongside weight loss, but once again, the magnitude and breadth of metabolic benefits dont match what Retatrutide delivers
Use a journal, notes app, or other tracking tool to record things like: When you take your medication Any side effects and when they occur Changes in body weight, appetite, or blood sugar Missed or delayed doses Bringing these notes to your check-ins can help guide any adjustments to your treatment plan